PDC Neo

PDC Neo (also written as PDC*neo) is an investigational, off-the-shelf cell therapy-based cancer vaccine developed by PDC*line Pharma, a spin-off of the French Blood Bank (EFS). The drug is built on the proprietary PDC*vac platform, which utilizes a potent, allogeneic plasmacytoid dendritic cell (PDC) line as the active cellular ingredient. PDC Neo is designed for personalized medicine by loading these allogeneic cells with patient-specific tumor neoantigens (tumor-specific somatic mutations) identified from the patient's tumor. The loaded cells are irradiated, packaged, and frozen for off-the-shelf distribution. Upon administration, the vaccine aims to prime and expand a robust anti-neoantigen CD8+ T-cell immune response to target and eliminate tumor cells. PDC Neo is primarily being developed for colorectal cancer, with additional research initiated for breast, liver, and bladder cancers.

Other names

PDC*neo